H.C. Wainwright lowered the firm’s price target on FibroBiologics (FBLG) to $4 from $5 and keeps a Buy rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Shareholders Approve Reverse Split, Warrant Issuances
- FibroBiologics granted extension by Nasdaq to regain compliance
- FibroBiologics Faces Nasdaq Delisting Review After Noncompliance
- FibroBiologics issued Canadian patent covering treatment of Cachexia
- FibroBiologics CEO says 2026 ‘will be about execution’